Key result
Prior statin therapy was not independently associated with elevated Lp(a) levels after multivariable adjustment.
Why the study?
Is prior statin therapy independently associated with increased plasma lipoprotein(a) levels in patients admitted for acute coronary syndrome?
Cross-Sectional (n=729)
Is prior statin therapy independently associated with increased plasma lipoprotein(a) levels in patients admitted for acute coronary syndrome?
In patients presenting with acute coronary syndrome, higher Lp(a) levels observed in prior statin users are driven by underlying cardiovascular risk and treatment indication rather than an independent statin effect, while elevated Lp(a) remains independently linked to prior ASCVD.
Answers are grounded in this paper and cite their sources.
Lp(a) elevation in statin-treated ACS patients likely reflects indication bias; supports Lp(a) as ASCVD marker but requires prospective confirmation.
The persistence of coronary events in statin-treated patients highlights residual risk mechanisms beyond low-density lipoprotein cholesterol (LDL-C), with lipoprotein(a) [Lp(a)] playing a relevant role. Statin therapy appears to be associated with increased plasma Lp(a) levels of uncertain significance, although the clinical significance of this association remains uncertain. This study primarily aimed to evaluate Lp(a) levels according to prior statin therapy in patients hospitalized for acute coronary syndrome (ACS). Secondarily, it assessed the association between Lp(a) and previous atherosclerotic cardiovascular disease (ASCVD). A total of 729 patients admitted for ACS with Lp(a) measurements were included. Clinical variables, lipid profile, statin treatment, and adherence were recorded. Multivariable binary logistic regression was used to assess the association between Lp(a) and prior statin therapy, followed by propensity score matching to account for differences in baseline characteristics. The association between Lp(a) and a prior diagnosis of ASCVD was also evaluated using logistic regression. Overall, 49.5% of patients had prior statin therapy. These subjects showed lower LDL-C and apoB, but higher Lp(a) levels (77 [26-181] vs. 56 [26-133] nmol/L; p = 0.009). However, this association lost significance after multivariable (OR 1.277; 95% CI 0.807-2.021; p = 0.296) and propensity score adjustment (p = 0.686). Conversely, elevated Lp(a) was independently associated with prior ASCVD (OR 1.638; 95% CI 1.115-2.405; p = 0.012). In conclusion, in ACS patients, the unadjusted association between prior statin therapy and higher Lp(a) concentrations is explained by baseline cardiovascular risk and treatment indication. In contrast, elevated Lp(a) levels are independently associated with a prior diagnosis of ASCVD, reinforcing their role as a marker of residual cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Meseguer-Hernández et al. (2026) conducted a cross-sectional in Acute coronary syndrome (ACS) (n=729). Prior statin therapy vs. No prior statin therapy was evaluated on Lipoprotein(a) [Lp(a)] levels according to prior statin therapy (OR 1.277, 95% CI 0.807-2.021, p=0.296). Prior statin therapy was not independently associated with elevated Lp(a) levels after multivariable adjustment.
Synapse has enriched 10 related papers. Consider them for comparative context: